ELDER WILLIAM ROBERT
Known title: GC & SecretaryCIK: 0001828068
ELDER WILLIAM ROBERT's purchase track record
How the stock did after each of ELDER WILLIAM ROBERT's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since August 27, 2024
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-49.8%
3 months: -35.2%
Beat the S&P 500
0%
median -58.5% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/12/2025 | CRVO | $55K | -35.2% | -49.8% | +8.7% |
| 5/14/2025 | CRVO | $36K | +15.9% | -10.9% | +16.3% |
| 8/27/2024 | CRVO | $18K | -52.1% | -87.0% | +5.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CRVO | ▲ Buy | Open Market | 2,500 | $21K | 11/18/2025 | View on chart |
| CRVO | ▲ Buy | Open Market | 1,000 | $8K | 11/17/2025 | View on chart |
| CRVO | ▲ Buy | Open Market | 3,500 | $26K | 11/12/2025 | View on chart |
| CRVO | ▲ Buy | Open Market | 4,233 | $36K | 5/14/2025 | View on chart |
| CRVO | ▲ Buy | Open Market | 1,000 | $18K | 8/27/2024 | View on chart |
| CRVO | ▼ Sell | Other | 100 | $3K | 4/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
CervoMed Reports PK Data and FDA Removal of Exposure Limit
CervoMed announced pharmacokinetic results for its new oral tablet formulation of neflamapimod. The company also secured the FDA's removal of a drug exposure limit, a regulatory update that may affect future development steps. These developments provide context for the stock's recent price movement within its 52-week range.
CervoMed Reports PK Data and FDA Removal of Exposure Limit. CervoMed announced pharmacokinetic results for its new oral tablet formulation of neflamapimod. The company also secured the FDA's removal of a drug exposure limit, a regulatory update that may affect future development steps. These developments provide context for the stock's recent price movement within its 52-week range.